Tessa Jaspers and Colleagues on Current Evidence Not Supporting Routine Anti-Xa Monitoring in Use of LMWH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins
LMWHs are widely used in diverse patient groups (renal impairment, pregnancy, obesity), but the value of anti-Xa monitoring remains unclear.
This systematic review of 48 studies (RCTs and observational) found:
- Comparable bleeding and VTE rates in monitored vs. unmonitored patients.
- Frequent dose adjustments in monitored cohorts.
- Weak or absent correlation between anti-Xa levels and clinical outcomes.
Current evidence does not support routine anti-Xa monitoring for LMWH dose adjustment.”
Read the full paper in JTH.
Article: A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins
Authors: Tessa C. C. Jaspers, P. Christian Remmelzwaal, Eefje P.S. Weersink, Karina Meijer, Nakisa Khorsand
Stay updated on all science in the field of anticoagulation with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis